| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DRNA | Common Stock | Options Exercise | $178K | +13.8K | +5111.52% | $12.93 | 14K | Jun 22, 2021 | Direct | |
| transaction | DRNA | Common Stock | Options Exercise | $51.5K | +2.28K | +16.26% | $22.58 | 16.3K | Jun 22, 2021 | Direct | |
| transaction | DRNA | Common Stock | Options Exercise | $57.9K | +2.41K | +14.76% | $24.05 | 18.7K | Jun 22, 2021 | Direct | |
| transaction | DRNA | Common Stock | Sale | -$503K | -13.6K | -72.47% | $37.10 | 5.15K | Jun 22, 2021 | Direct | F1, F2 |
| transaction | DRNA | Common Stock | Sale | -$179K | -4.88K | -94.78% | $36.71 | 269 | Jun 22, 2021 | Direct | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DRNA | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -13.8K | -13.92% | $0.00 | 85K | Jun 22, 2021 | Common Stock | 13.8K | $12.93 | Direct | F4 |
| transaction | DRNA | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -2.28K | -4.34% | $0.00 | 50.2K | Jun 22, 2021 | Common Stock | 2.28K | $22.58 | Direct | F5 |
| transaction | DRNA | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -2.41K | -4.18% | $0.00 | 55.1K | Jun 22, 2021 | Common Stock | 2.41K | $24.05 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | The Reporting Person sold an aggregate of 18,435 shares of Common Stock on June 22, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 7.75% of 237,824 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. |
| F2 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.35, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| F3 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.625 to $36.865, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. |
| F4 | The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date. |
| F5 | The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2020, and the remaining vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date. |
| F6 | The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2021, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date. |